24/7 Wall St. has generated a bullish and bearish scenario for 2014 in each stock of the Dow, including Pfizer Inc. (NYSE: PFE) and rival Merck & Co. (NYSE: MRK). Both of these pharmaceutical giants are defensive stocks by nature, yet …
Pfizer Inc. (NYSE: PFE) today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND® (voriconazole) and ERAXISTM (anidulafungin) to VFEND monotherapy for primary therapy of …
Pfizer Inc. (NYSE:PFE) is expected to focus on the development of new ... likely speeding up its final testing and …
Pfizer Inc. (NYSE: PFE) shareholders have experienced the short-term euphoria of seeing their stock rally a massive 10 percent from August to September. The stock failed to eclipse key “triple threat” resistance (created by a horizontal line ...
The drugmaker's stock slipped 1 percent, but the fallout is minimal. Crestor is already an FDA-approved blockbuster. Sales of the drug soared 42 percent during the first nine months of 2007, reaching nearly $2 billion. Merck had better luck with …